In its Q1 2026 filing, iRhythm Holdings demonstrated revenue growth driven by sustained demand for its proprietary Zio patch and cloud-based cardiac monitoring services. The company continues to expand its market presence with approximately 40% penetration in the U.S. ambulatory cardiac monitoring arena. However, regulatory pressures surrounding Medicare reimbursement frameworks, device compliance, and ongoing legal proceedings remain material headwinds. iRhythm’s integrated device-software-service model, supported by a Medicare-enrolled IDTF infrastructure and extensive clinical data, underpins competitive differentiation and positions it for measured international expansion. Key risks include reimbursement uncertainty, supply chain vulnerabilities, and evolving FDA oversight dynamics.